Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: Results from a US database of over 45 000 HCV-infected, evaluated patients

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 4, 2013, Pages 473-481

  Talal, A H ^a   Lafleur, J ^b   Hoop, R ^c   Pandya, P ^d   Martin, P ^e   Jacobson, I ^f   Han, J ^c   Korner, E J ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c GENENTECH INC   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; PEGINTERFERON; RIBAVIRIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGE; AGED; ANEMIA; ARTICLE; BIPOLAR DISORDER; CAUCASIAN; CHILD; DATA BASE; DECOMPENSATED LIVER CIRRHOSIS; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; FEMALE; HEMOGLOBINOPATHY; HEPATITIS C; HUMAN; ICD-9; INFANT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MARRIAGE; MEDICAID; MEDICARE; NEUTROPENIA; NEUTROPHIL COUNT; ORGAN TRANSPLANTATION; PREGNANCY; PRIORITY JOURNAL; RETINOPATHY; SEIZURE; SEX DIFFERENCE; SUICIDE ATTEMPT; THROMBOCYTE COUNT; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFANT; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84872678855     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12200     Document Type: Article

References (21)

1. Lavanchy D,. The global burden of hepatitis C. Liver Int 2009; 29 (Suppl. 1): 74-81.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S,. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.
3. Lauer GM, Walker BD,. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
4. Rein DB, Smith BD, Wittenborn JS, et al,. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med 2012; 156: 263-70.
5. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
6. McHutchison JG, Gordon SC, Schiff ER, et al,. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
7. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ,. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-92.
8. El-Serag HB, Kunik M, Richardson P, Rabeneck L,. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-82.
9. Rowan PJ, Tabasi S, Abdul-Latif M, Kunik ME, El-Serag HB,. Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 2004; 38: 530-4.
10. Lehman CL, Cheung RC,. Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2640-6.
11. Butt AA, Wagener M, Shakil AO, Ahmad J,. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12: 81-5.
12. Muir AJ, Provenzale D,. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002; 34: 268-71.
13. Bini EJ, Brau N, Currie S, et al,. Prospective multicenter study of eligibility for antiviral therapy among 4,084 U.S. veterans with chronic hepatitis C virus infection. Am J Gastroenterol 2005; 100: 1772-9.
14. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK,. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56: 385-9.
15. US Census Bureau. Annual estimates of the resident population for the United States, regions, states, and Puerto Rico: April 1, 2000 to July 1, 2009. Available at: http://www.census.gov/popest/data/historical/2000s/vintage-2009/ index.html. Accessed October 17, 2011.
16. Ghany MG, Strader DB, Thomas DL, Seeff LB,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
17. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D,. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36: 97-100.
18. Goulet JL, Fultz SL, McGinnis KA, Justice AC,. Relative prevalence of comorbidities and treatment contraindications in HIV-mono-infected and HIV/HCV-co-infected veterans. AIDS 2005; 19 (Suppl. 3): S99-105.
19. McHutchison JG, Everson GT, Gordon SC, et al,. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-38.
20. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
21. Seden K, Back D,. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions. Curr Opin HIV AIDS 2011; 6: 514-26.